On November 15, 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an exclusive option to acquire the company and its AcuStream technology. The agreement follows a feasibility study agreement with the AcuStream technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the two parties is ongoing. The financial and other terms of this transaction have not been disclosed.
Wilson Sonsini Goodrich & Rosati represented Kedalion on both transactions. The team included:
Corporate/M&A
Ken Clark
Michael Coke
Ethan Lutske
Kenji Strait
IP/Technology Transactions
Lowell Segal
Norman Hovijitra
Miruna Predescu
Tony Nguyen
Employment
Rebecca Stuart
Briza Sanchez
Employee Benefits and Compensation
Scott McCall
Michael Klippert
Jason Chan
FDA/Regulatory
David Hoffmeister
Eva Yin
For more information, please see Kedalion's press release.